PPT-The Evolution of Cardiovascular Outcomes Trials in T2DM Over the Years

Darren K McGuire MD MHSc Professor of Medicine University of Texas Southwestern Medical Center Conflict of Interest Disclosure Clinical Trials Leadership Takeda Merck Astra Zeneca Janssen. Bio . HL. Full Classification of Humans. Kingdom - . Animalia. Phylum - . Chordata. Class - Mammalia. Order - . Primata. Family - . Hominidae. Genus - Homo. Species - Homo sapiens. subspecies - H. s. sapiens. 2. Center for Healthcare Studies, . 3. Center for Health Information Partnerships, . 4. Emergency Medicine, . 5. Preventive Medicine, . 6. Institute for Public Health and Medicine. Background. 117 million people in the US suffered from a chronic disease in 2012 . Agenda. Introduction/Background. CV Safety With Intensive Glucose Lowering. Regulatory Request for CV Safety Trials. ORIGIN Trial. DEVOTE: . Study Drugs. Rationale for DEVOTE Trial. DEVOTE Baseline Characteristics. FDA-Mandated CV Safety Trials. 1. TECOS. (Trial Evaluating Cardiovascular Outcomes with Sitagliptin). Clinical Outcomes with Antihyperglycemic Agents. 2. Clinical Outcomes with Sitagliptin. Study Design. Chapter Overview Questions. How do scientists account for the development of life on earth?. What is biological evolution by natural selection, and how can it account for the current diversity of organisms on the earth?. wabat@southern-med.com. PLATINUM DIVERSITY STUDY. National Co-PI. The first U.S. national study prospectively evaluating the clinical outcomes of 1,500 women and minorities undergoing coronary artery stenting. Enrollment completed. Fully funded by Industry. Focusing on Triglycerides. Primary and Secondary CVD Prevention Trials: . Evaluating Treatment of Triglycerides. Why Have Outcomes Trials of TG-Lowering Drugs Failed to Reach Primary Endpoints? . ASCEND . CVOTs. 1. FDA CVOT Guidance—2008. Timeline of Major Diabetes. Outcomes Trials. 2. Blue. = Intensive vs standard control using same set of glucose-lowering agent(s). Purple. = Intensive control with a specific agent vs standard care. 1intermediate vascular traits and all-cause mortality a systematic review and meta-analysis of observational studiesTaulant Muka MD PhD1 Clare Oliver-Williams PhD2 Setor Kunutsor MD PhD2 Joop SE Laven Antidiabetes. Medications:. Cardiovascular Benefits. Hengameh. . Abdi. Endocrine Research Center. Research Institute for Endocrine sciences. Shahid. . Beheshti. University of Medical Sciences. 13 December 2018. T2DM 1. Cyto. T2DM 5. Cyto. ND 4. Cyto. ND 5. Cyto. T2DM 6. Cyto. ND 3. Cyto. T2DM 4. Cyto. ND 1. Cyto. ND 6. Cyto. T2DM 2. Mito ND 1. Mito T2DM 1. Mito T2DM 6. Mito ND 2. Mito T2DM 4. Mito T2DM 2. in Uganda. Prof. Kirsty Le . Doare. 14. th. March 2022. Preparation for maternal vaccine studies. Pregnancy is associated with complications (stillbirth, premature birth . etc. ) that must be differentiated from vaccine associated adverse events.. Backgrounde International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM) []. People with diabetes comprise 8.8% NT-. proBNP. . concentrations identify . T2DM . patients at high risk for major . CV . events. A subanalysis of the EXAMINE study (N=1,306 in each NT-proBNP group) . Primary endpoint: CV . death, non-fatal myocardial .